Skip to main content
Equibles
CSTL logo

CSTL · Castle Biosciences Inc

Track CSTL — free

Use CSTL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CSTL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$33.50 -0.76 (-2.22%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$1.06B
Shares
30.55M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$33.50 Open$34.02 Day$32.80–34.28 52W close$18.15–43.04 Avg vol 30d476K Short int1.8M · 5.7% float · 3.7d Short vol37% Last earningsJul 30, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 26, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Bearish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +14%
      above
      Price vs 50-day avg +23%
      above
      RSI (14) 63
      neutral
      MACD trend Positive
      52-week position 62%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +20%
      trailing
      6-month return +24%
      trailing
      YTD return −14%
      this year
      Relative strength +11%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $27 › 200d $29 — 200d above 50d
      Institutional flow Distributing
      -5% holders QoQ · +24 funds added
      Insider flow Distributing
      Net -$1.6M over 90 days · 100% sells
      Short interest Rising
      5.74% of float · ▲ +12.3% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      177 holders — mid 3-yr range
      Squeeze score 60
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +4%
      Y/Y
      Gross margin 15%
      expanding
      EPS growth −234%
      Y/Y
      Free cash flow $28.3M
      Balance sheet $106.7M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 57%
      annualized · 1-yr
      Max drawdown −58%
      past year
      ATR 5.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 4 of last 4
      Latest guidance · from the 8-K filed Jul 30, 2026
      Total revenue · full year 2026 Raised $365M – $375M
      May 6, 2026 $345M – $355M changed to Jul 30, 2026 $365M – $375M
      prior FY $344.23M midpoint +7.5% Y/Y
      Prior guidance period ended · from the 8-K filed Nov 3, 2025
      Total revenue · full-year 2025 $327M – $335M
      Guided vs delivered · last 4 settled
      Total revenue full-year 2025
      guided $327M – $335M
      $344.23M Beat +4.0%
      Total revenue 2024
      guided $235M – $240M
      $332.07M Beat +39.8%
      Total revenue full year 2023
      guided at least $200M
      $219.79M In line
      Total revenue full year 2022
      guided $132M – $137M
      $137.04M Beat +1.9%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +14% Bullish
      Price vs 50-day avg
      +23% Bullish
      RSI (14)
      63 Neutral
      MACD trend
      Positive Bullish
      52-week position
      62% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $27 › 200d $29 — 200d above 50d
      Institutional flow Distributing
      -5% holders QoQ · +24 funds added
      Insider flow Distributing
      Net -$1.6M over 90 days · 100% sells
      Short interest Rising
      5.74% of float · ▲ +12.3% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      177 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $18 Now $34 · 62% Range high $43
      vs 200-day avg +14% vs 50-day avg +23%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Cash Position $266.8M As of June 30, 2026 —
      DecisionDx-Melanoma test reports delivered in 2026 20,301 Six Months Ended June 30, 2026 —
      DecisionDx-SCC test reports delivered in 2026 7,713 Six Months Ended June 30, 2026 —
      DecisionDx-UM test reports delivered in 2026 974 Six Months Ended June 30, 2026 —
      MyPath Melanoma test reports delivered in 2026 2,034 Six Months Ended June 30, 2026 —
      TissueCypher Barrett's Esophagus test reports delivered in 2026 26,733 Six Months Ended June 30, 2026 —
      TissueCypher test reports delivered in the quarter 14,988 2Q26 —
      Adjusted Gross Margin percentage non-GAAP 75.6% Three Months Ended March 31, 2026 —
      Adjusted Net (Loss) Income per Share, Basic (Non-GAAP) non-GAAP -$0.14 Twelve Months Ended December 31, 2025 —
      Adjusted Net (Loss) Income per Share, Diluted (Non-GAAP) non-GAAP -$0.14 Twelve Months Ended December 31, 2025 —
      clinicians ordering DecisionDx-SCC 7,380 as of December 31, 2025 —
      DecisionDx-Melanoma and TissueCypher combined test reports growth 37% Full Year 2025 —
      DecisionDx-Melanoma test reports delivered in 2025 39,083 Twelve Months Ended Dec. 31, 2025 —
      DecisionDx-SCC test reports delivered in 2025 17,294 Twelve Months Ended Dec. 31, 2025 —
      DecisionDx-UM test reports delivered in 2025 1,769 Twelve Months Ended Dec. 31, 2025 —
      IDgenetix test reports delivered in 2025 3,605 Twelve Months Ended Dec. 31, 2025 —
      MyPath Melanoma lesions tested clinically 50,000 as of December 31, 2025 —
      MyPath Melanoma test reports delivered in 2025 4,288 Twelve Months Ended Dec. 31, 2025 —
      Net cash provided by operations $64.3M Full Year 2025 —
      patients with a clinical DecisionDx-SCC order 59,250 as of December 31, 2025 —
      TissueCypher Barrett's Esophagus test reports delivered in 2025 39,014 Twelve Months Ended Dec. 31, 2025 —
      Total Test Reports 27,236 4Q25 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CSTL
      Castle Biosciences Inc
      this stock
      		$1.06B -13.9% +3.7% — 5.7%
      TMO
      Thermo Fisher Scientific Inc.
      		 $230.05B +7.4% +14.5% 33.5 1.3%
      DHR
      Danaher Corp /De/
      		 $151.51B -5.6% +8.5% 38.2 1.2%
      NTRA
      Natera, Inc.
      		 $48.82B +42.4% -2.8% — 3.0%
      IQV
      Iqvia Holdings Inc.
      		 $43.79B +16.1% +41.6% 32.6 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      177
      % held
      89.5%
      Net QoQ
      -345.1K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      237
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.8M
      Days to cover
      3.7d
      Change
      +191.6K sh
      View
      Short Volume
      Short vol %
      37%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      172
      Value
      $4.2K
      As of
      Jul 22, 2026
      View
      Off-Exchange
      Off-exchange %
      33.6%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$1.6M
      Buyers / Sellers
      0 / 2
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Josh Gottheimer
      Amount
      $1.0K–$15.0K
      Traded
      Mar 15, 2022
      View
      Financials
      Financials
      Revenue (FY)
      $344.2M
      Net income (FY)
      $-24.2M
      EPS diluted
      $-0.83
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $741.5K
      Shares
      24.9K
      Filed
      Aug 14, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 15, 2026
      Last call
      Aug 12, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      CSTL -2.1% +19.6% +24.0% +19.6% -13.9%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY -2.5% +16.7% +10.6% +16.7% -26.7%
      Key facts CIK 1447362 CUSIP 14843C105 13F (30d) 149 filings 149 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)